- cafead   Oct 17, 2023 at 12:02: PM
via Janssen Pharmaceuticals has announced that its Tremfya (guselkumab) demonstrated improving rates of clinical remission and endoscopic response maintained across the three-year Phase II Crohn’s disease study.
article source
article source